Category: 400715-69-7

On February 28, 2002, Myers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.HPLC of Formula: 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides with nicotinic acetylcholine receptor binding activity for pharmaceutical use. And the patent contained the following:

N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).HPLC of Formula: 400715-69-7

The Article related to quinuclidine heteroaryl preparation nicotinic receptor binding, Alkaloids: Alkaloids Containing Two Nitrogen Atoms and other aspects.HPLC of Formula: 400715-69-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On February 28, 2002, Meyers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.Product Details of 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders. And the patent contained the following:

N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as cognitive and attention deficit symptoms of Alzheimer’s, neurodegeneration associated with diseases such as Alzheimer’s disease, pre-senile dementia (mild cognitive impairment), or senile dementia. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).Product Details of 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Product Details of 400715-69-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On February 28, 2002, Myers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.Computed Properties of 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders. And the patent contained the following:

N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down’s syndrome, dementia associated with Lewy Bodies, Huntington’s disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson’s disease, tardive dyskinesia, Pick’s disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette’s Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).Computed Properties of 400715-69-7

The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Computed Properties of 400715-69-7

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics